Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Semler Scientific, Inc. filings document its common-stock status, material events and public-company reporting history. Recent regulatory records include Form 25 disclosure for removal of the common stock from Nasdaq listing and registration, and Form 15 certification covering termination or suspension of Exchange Act reporting obligations for the class of securities.
The company's 8-K filings cover material agreements, shareholder voting matters, governance items, capital-structure disclosures and operating and financial results. Filing categories also address risk factors and clinical or regulatory matters tied to Semler Scientific's healthcare technology activities, alongside disclosures related to its Bitcoin treasury strategy.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific (SMLR). The notice, reposted by a Strive director on X.com, includes a forward‑looking statements caution and directs investors to upcoming proxy materials.
Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. Documents will be available free of charge on the SEC’s website and each company’s investor site. The communication states it is not an offer or solicitation to buy or sell securities.
Strive, Inc. announced a proposed business combination with Semler Scientific via a Form 425 communication referencing a post on X.com dated November 10, 2025. Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction, and Semler Scientific stockholders will receive an information statement/proxy statement/prospectus to consider and vote on the deal. The communication includes extensive forward-looking statement cautions and directs investors to SEC filings for details. It also states this is not an offer or solicitation to sell securities.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive has filed a Form S-4 to register the Class A common stock to be issued in the transaction, which will include an information statement, proxy statement, and prospectus.
Semler Scientific stockholders will receive a definitive proxy/prospectus to vote on the deal. The communication includes forward‑looking statement cautions, explains how to access SEC filings, notes potential proxy “participants,” and clarifies it is not an offer to sell or solicit securities.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in connection with the transaction. A combined information statement/proxy statement/prospectus will be sent to Semler Scientific stockholders to seek their approval.
The communication includes forward-looking statement cautions and directs investors to the SEC’s website and company investor pages for the Registration Statement and related materials when available.
Strive, Inc. released a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR), which was reposted on X.com by board member Pierre Rochard on November 10, 2025.
Strive has filed a Form S-4 to register Class A common stock to be issued in connection with the transaction. The S-4 includes an information statement/proxy statement/prospectus, and a definitive version will be sent to Semler stockholders to seek their approval.
The notice includes forward‑looking statement cautions, directs investors to the SEC and company websites for documents, identifies potential proxy solicitation participants, and states it is not an offer or solicitation.
Strive, Inc. filed a Rule 425 communication related to its proposed business combination with Semler Scientific (SMLR). The notice includes a forward‑looking statements caution and outlines that Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction. The S‑4 will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive.
Semler Scientific stockholders will receive a definitive Information Statement/Proxy Statement/Prospectus to consider and vote on the proposed transaction. Investors are urged to read these materials when available, as they will contain important details about the companies and the deal. The communication emphasizes it is not an offer or solicitation to sell securities. Documents will be available free of charge on the SEC’s website and the companies’ investor relations pages.
Semler Scientific (SMLR) and Strive, Inc. announced a transaction-related communication under Rule 425, tied to their proposed business combination. The notice emphasizes forward-looking statement cautions and outlines the path to closing.
Strive has filed a Form S-4 to register the Class A common stock to be issued in the deal, which will include an information statement/proxy statement/prospectus. A definitive version will be sent to Semler Scientific stockholders to seek their approval. Investors are directed to review the S-4 and related materials when available on the SEC’s website and each company’s investor relations pages. The communication also clarifies this is not an offer to sell or solicit the purchase of securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The notice emphasizes forward‑looking statement cautions and directs investors to official SEC materials.
Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction. A combined information statement, proxy statement, and prospectus will be sent to Semler stockholders to seek approval. The companies note that this is not an offer or solicitation and urge investors to read the Registration Statement and related documents when available.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The communication includes forward‑looking statement cautions and states it is not an offer or solicitation. Related documents, when available, can be obtained free of charge from the SEC’s website and each company’s investor relations pages.
Semler Scientific and Strive announced a proposed business combination and related investor communications filed under Rule 425. Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement for Strive, a proxy statement for Semler Scientific, and a prospectus for Strive. Semler Scientific stockholders will receive definitive proxy materials to vote on the deal.
The communication emphasizes forward-looking statement cautions and directs investors to SEC filings for details, including Strive’s S-4 filings dated August 6, 2025 and October 10, 2025, and each company’s periodic reports. It clarifies this is not an offer to sell or buy securities; any offer will be made only by a prospectus meeting Section 10 of the Securities Act or an applicable exemption.